Maurice B. Loughrey

Maurice B. Loughrey

Auto-generated profile, based on publicly available information

Maurice B. Loughrey

Department of Cellular Pathology Belfast Health and Social Care Trust Belfast UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2025 in Gut
Verified
Journal Article
Open access
PDF file
GMGordon W. Moran
Gordon W. Moran
MGMorris Gordon
Morris Gordon
VSVassiliki Sinopoulou
Vassiliki Sinopoulou
SRShellie J Radford
Shellie J Radford
ADAna-Maria Darie
Ana-Maria Darie
NWNewton A C S Wong
Newton A C S Wong
In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revised in 2019. These updated guidelines aim to complement the IBD standards and promote the use of the national primary care diagnostic pathway for lower gastrointestinal symptoms to enhance diagnostic accuracy and timeliness. Formulated through a systematic and transparent process, this document reflects a consensus of best practices based on current evidence. The guideline, while developed primarily for the UK, is structured to support IBD management internationally. It is endorsed by the BSG executive board and CSSC without external commercial funding, with involvement primarily supported through professional roles in public institutions and the National Health Service (NHS). Methodological revisions since the prior guidelines have enhanced rigor in technical review and development, with methodology details published independently following peer review. In developing the recommendations, 89 clinical experts and stakeholders participated in an online survey, identifying primary outcomes, such as clinical and endoscopic remission, as well as adverse event metrics, all stratified by clinically relevant effect sizes. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges.

7 December 2023 in Medical Image Analysis
Verified
Journal Article
Open access
DTDaniel Truhn
Daniel Truhn
...... ....
.... ....
OSOliver Lester Saldanha
Oliver Lester Saldanha
GMGustav Müller-Franzes
Gustav Müller-Franzes
FKFiras Khader
Firas Khader
JKJakob Nikolas Kather
Jakob Nikolas Kather
Artificial intelligence (AI) has a multitude of applications in cancer research and oncology. However, the training of AI systems is impeded by the limited availability of large datasets due to data protection requirements and other regulatory obstacles. Federated and swarm learning represent possible solutions to this problem by collaboratively training AI models while avoiding data transfer. However, in these decentralized methods, weight updates are still transferred to the aggregation server for merging the models. This leaves the possibility for a breach of data privacy, for example by model inversion or membership inference attacks by untrusted servers. Somewhat-homomorphically-encrypted federated learning (SHEFL) is a solution to this problem because only encrypted weights are transferred, and model updates are performed in the encrypted space. Here, we demonstrate the first successful implementation of SHEFL in a range of clinically relevant tasks in cancer image analysis on multicentric datasets in radiology and histopathology. We show that SHEFL enables the training of AI models which outperform locally trained models and perform on par with models which are centrally trained. In the future, SHEFL can enable multiple institutions to co-train AI models without forsaking data governance and without ever transmitting any decryptable data to untrusted servers.

13 August 2020 in Histopathology
Verified
Journal Article
Open access
PDF file
MLMaurice B Loughrey
Maurice B Loughrey
JMJason McGrath
Jason McGrath
HCHelen G Coleman
Helen G Coleman
PBPeter Bankhead
Peter Bankhead
PMPerry Maxwell
Perry Maxwell
JJJacqueline A James
Jacqueline A James
Aims: Establishing the mismatch repair (MMR) status of colorectal cancers is important to enable the detection of underlying Lynch syndrome and inform prognosis and therapy. Current testing typically involves either polymerase chain reaction (PCR)‐based microsatellite instability (MSI) testing or MMR protein immunohistochemistry (IHC). The aim of this study was to compare these two approaches in a large, population‐based cohort of stage 2 and 3 colon cancer cases in Northern Ireland.Methods and results: The study used the Promega pentaplex assay to determine MSI status and a four‐antibody MMR IHC panel. IHC was applied to tumour tissue microarrays with triplicate tumour sampling, and assessed manually. Of 593 cases with available MSI and MMR IHC results, 136 (22.9%) were MSI‐high (MSI‐H) and 135 (22.8%) showed abnormal MMR IHC. Concordance was extremely high, with 97.1% of MSI‐H cases showing abnormal MMR IHC, and 97.8% of cases with abnormal IHC showing MSI‐H status. Under‐representation of tumour epithelial cells in samples from heavily inflamed tumours resulted in misclassification of several cases with abnormal MMR IHC as microsatellite‐stable. MMR IHC revealed rare cases with unusual patterns of MMR protein expression, unusual combinations of expression loss, or secondary clonal loss of expression, as further illustrated by repeat immunostaining on whole tissue sections.Conclusions: MSI PCR testing and MMR IHC can be considered to be equally proficient tests for establishing MMR/MSI status, when there is awareness of the potential pitfalls of either method. The choice of methodology may depend on available services and expertise.

25 March 2018 in Histopathology
Verified
Journal Article
Closed access
PDF file
MLMaurice B Loughrey
Maurice B Loughrey
PBPeter Bankhead
Peter Bankhead
HCHelen G Coleman
Helen G Coleman
RHRyan S Hagan
Ryan S Hagan
SCStephanie Craig
Stephanie Craig
MSManuel Salto‐Tellez
Manuel Salto‐Tellez

1 October 2017 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Open access
IFIfewumi O. Fagunwa
Ifewumi O. Fagunwa
MLMaurice B. Loughrey
Maurice B. Loughrey
HCHelen Coleman
Helen Coleman
Colorectal cancer (CRC) is the third most common cancer worldwide and has a complex aetiology consisting of environmental and genetic factors. In this review, we evaluate the roles of alcohol and tobacco smoking in colorectal neoplasia. Alcohol intake and tobacco smoking are associated with modest, but significantly, increased risks of CRC, adenomatous and serrated polyps. There is consistent evidence of dose-response relationships for both alcohol and smoking, and risk of these neoplasms. Alcohol and smoking appear to be more strongly associated with colorectal polyp than CRC development, suggesting roles in the initiation of neoplastic growths. These lifestyle factors also seem more strongly related to adenomas and sessile serrated lesions than hyperplastic polyps, but further confirmation is required. The gastroenterology community has an important, yet currently underexploited, role to play addressing the modifiable factors associated with CRC and polyps. These behaviours include, but are not limited to, alcohol and smoking.

28 January 2021 in Histopathology
Verified
Journal Article
Closed access
PDF file
ALAmy Lord
Amy Lord
GBGina Brown
Gina Brown
MAMuti Abulafi
Muti Abulafi
Adrian Calvin BatemanAdrian Calvin Bateman
Adrian Calvin Bateman
WFWendy Frankel
Wendy Frankel
INIris D. Nagtegaal
Iris D. Nagtegaal